GFRA3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1746652	0.63	8/20
SCHEMBL1747049	0.58	8/20
SCHEMBL16844693	0.52	7/20
SCHEMBL1744666	0.53	5/20
SCHEMBL3089215	0.40	3/20
SCHEMBL1745124	0.52	2/20
SCHEMBL1746725	0.50	2/20
SCHEMBL27692141	0.48	2/20
SCHEMBL1746615	0.48	2/20
SCHEMBL8530467	0.46	2/20
SCHEMBL1746643	0.43	2/20
SCHEMBL21142559	0.43	2/20
SCHEMBL17200608	0.43	2/20
SCHEMBL21810402	0.43	2/20
SCHEMBL28996985	0.41	2/20
SCHEMBL13630180	0.41	2/20
SCHEMBL20953608	0.41	2/20
SCHEMBL25474368	0.37	2/20
SCHEMBL1744877	0.62	1/20
SCHEMBL1736682	0.54	1/20

Clinical trials — most relevant to GFRA3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
Valproate and Levocarnitine in Children With Spinal Muscular Atrophy	PHASE3	UNKNOWN
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision	PHASE3	COMPLETED
Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients	PHASE3	COMPLETED
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment	PHASE2	COMPLETED
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
Cilostazol in Parkinson's Disease	PHASE2	NOT_YET_RECRUITING
Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease	PHASE2	COMPLETED
Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib	PHASE1/PHASE2	COMPLETED
Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders	PHASE1/PHASE2	COMPLETED
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)	PHASE2	COMPLETED
GDNF in ideopathicParkinsons Disease	PHASE2	COMPLETED
Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome	PHASE1/PHASE2	COMPLETED
AAV2-GDNF for Advanced Parkinson s Disease	PHASE1	COMPLETED
Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in SCI	PHASE1	COMPLETED
Gene Therapy for Alzheimer's Disease Clinical Trial	PHASE1	COMPLETED
GDNF Gene Therapy for Parkinson's Disease	PHASE1	ACTIVE_NOT_RECRUITING
Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder	nan	UNKNOWN
Association of Urine BDNF and NGF With Lower Urinary System Parameters	nan	RECRUITING
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Cryopreservation of Prepubertal Testicular Tissue for Preservation of Fertility in Young Boys With Cancer	nan	RECRUITING
Regulation of Stem Spermatogonia in the Mature Testis	nan	COMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Cord Blood Serum in the Treatment of Neuro-Degenerative Ophthalmic Diseases. 1-Glaucoma	nan	COMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
Establishment of Biomarkers for Fabry Disease	nan	COMPLETED
Leukemia Inhibitory Factor Level in Intrauterine Growth Restriction Neonates	nan	UNKNOWN
The Role of Epigenetic Modifications in Autism Spectrum Disorder	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a GFRA3 binder may also engage these)

Protein	Name	Similarity
O35118	—	1.000	O35118 →
O93512	—	0.985	O93512 →
Q9EPI2	—	0.982	Q9EPI2 →
Q5XHC5	—	0.978	Q5XHC5 →
P51653	—	0.978	P51653 →
D3ZB94	—	0.976	D3ZB94 →
P16042	—	0.976	P16042 →
Q8IVN8	—	0.976	Q8IVN8 →
Q6GUQ1	—	0.976	Q6GUQ1 →
Q9JJT2	—	0.976	Q9JJT2 →
Q3S2X5	—	0.976	Q3S2X5 →
A4IIA2	—	0.975	A4IIA2 →
O08545	—	0.975	O08545 →
P15306	—	0.975	P15306 →
P59383	—	0.974	P59383 →
Q2PE73	—	0.974	Q2PE73 →
Q6UXV0	—	0.974	Q6UXV0 →
Q8BKV1	—	0.974	Q8BKV1 →
Q9DBX3	—	0.974	Q9DBX3 →
Q7TQH7	—	0.974	Q7TQH7 →
Q29016	—	0.974	Q29016 →
A6NFU0	—	0.974	A6NFU0 →
Q99988	—	0.974	Q99988 →
A0A286YEC0	—	0.974	A0A286YEC0 →
P0DN86	—	0.974	P0DN86 →
Q8N158	—	0.974	Q8N158 →
Q9NPY3	—	0.974	Q9NPY3 →
Q8C2S7	—	0.974	Q8C2S7 →
Q62005	—	0.974	Q62005 →
Q3V140	—	0.974	Q3V140 →